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 BONE BIOLOGY
Human osteoblasts obtained from 
distinct periarticular sites demonstrate 
differences in biological function in vitro
Aims
Accumulated evidence indicates that local cell origins may ingrain differences in the pheno-
typic activity of human osteoblasts. We hypothesized that these differences may also exist in 
osteoblasts harvested from the same bone type at periarticular sites, including those adja-
cent to the fixation sites for total joint implant components.
Methods
Human osteoblasts were obtained from the acetabulum and femoral neck of seven patients 
undergoing total hip arthroplasty (THA) and from the femoral and tibial cuts of six patients 
undergoing total knee arthroplasty (TKA). Osteoblasts were extracted from the usually dis-
carded bone via enzyme digestion, characterized by flow cytometry, and cultured to passage 
three before measurement of metabolic activity, collagen production, alkaline phosphatase 
(ALP) expression, and mineralization.
Results
Osteoblasts from the acetabulum showed lower proliferation (p = 0.034), cumulative col-
lagen release (p < 0.001), and ALP expression (p = 0.009), and produced less mineral (p = 
0.006) than those from the femoral neck. Osteoblasts from the tibia produced significantly 
less collagen (p = 0.021) and showed lower ALP expression than those from the distal femur.
Conclusion
We have demonstrated for the first time an anatomical regional variation in the biological 
behaviours of osteoblasts on either side of the hip and knee joint. The lower osteoblast pro-
liferation, matrix production, and mineralization from the acetabulum compared to those 
from the proximal femur may be reflected in differences in bone formation and implant 
fixation at these sites.
Cite this article: Bone Joint Res 2021;10(9):611–618.
Keywords: Osteoblast, Arthroplasty, Aseptic loosening
Article focus
 The aim of this study was to establish if 
different anatomical sites and hence envi-
ronments could account for differences in 
osteoblast function at periarticular sites.
 We hypothesized that bone- forming 
human osteoblasts differ in their func-
tional capabilities depending on their 
anatomical source.
Key messages
 Human osteoblasts demonstrated 
different functional outcomes in the 
assays conducted in this study.
 Our study found coincidentally that 
human osteoblasts harvested from sites 
more readily associated with earlier 
failure with regards to arthroplasty, and 
performed less favourably in the func-
tional assays performed in human osteo-
blasts isolated from native hip and knee 
joints.
Strengths and limitations
 The study showed consistent anatom-
ical variations in human osteoblast 
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proliferation, cumulative collagen release, alkaline 
phosphatase expression, and mineral production.
 The main limitation of the study is that the number of 
patient samples could be increased, and we acknowl-
edge that the data, while statistically significant, are 
preliminary.
Introduction
Earlier work within our laboratory established that an 
area that has not been evaluated is whether an asym-
metric biological difference exists in bone- forming osteo-
blast function.
Primary hip and knee arthroplasty surgery continues 
to increase nationally1 and globally2 with revision rates 
of arthroplasty surgery and their causes being oblig-
atory measures of total joint replacement outcome 
success.3-7 The current approach to increasing the 
longevity of implant components is to modify implant 
designs and materials,8 and the lifetime risk of requiring 
revision surgery over the age of 70 years is approxi-
mately 5%.9 The authors from the same study showed 
up to a 35% chance of revision for males undergoing 
primary surgery in their 50s and 20% for females in the 
same age group.9 They estimated a median time to revi-
sion of 4.4 years in those who had surgery under the 
age of 60 years. It is also estimated that the number of 
revision total knee arthroplasties (TKAs) will increase by 
601% by 2030.10
The clinical and economic impact of revision total hip 
arthroplasty (THA) and TKA has been estimated and well 
described.11,12 It poses a significant burden on patients, 
healthcare professionals, and healthcare systems by way 
of higher complications and blood transfusion require-
ment, prolonged operating time, and increased length 
of stay.13-15 Not only are direct costs increasing, but 
some have estimated associated costs of up to £75,000 
per patient.16,17 Better understanding of the underlying 
bone biology could direct treatment, reduce the need for 
surgical intervention of any kind, and thus bring huge 
benefits.
Evidence exists of a variation in the phenotype of 
bone- forming osteoblasts depending on their skeletal 
location in both animal and human models.18-20 Specif-
ically, human osteoblasts isolated from trabecular bone 
showed lower proliferation than those from cortical and 
sub- chondral bone, but higher expression of differentia-
tion markers when obtained from human adult humeri. 
Differences were consistent between cells from patients 
with osteoarthritis (OA), osteoporosis, and from a single 
patient without bone pathology.21 One of the limitations 
of this analysis is that human osteoblasts were acquired 
from different bone types and obtained via outgrow 
methods, whereby cells are permitted to grow out of 
bone specimens without using enzyme digestion.
While these studies provide evidence of osteoblast 
variability, there have been no studies reporting anatom-
ical variation in osteoblast function specifically from 
periarticular regions from the hip and knee, and from the 
same bone type.
We hypothesize that differences in biological behaviour 
of cells isolated from different sites may exist, and have 
performed biological assays of human osteoblasts to 
establish if the underlying cell biology could be a consid-
eration with regards to surgical outcomes.
Methods
Study design. A level II prospective cohort laboratory 
study was performed.
Patient recruitment and evaluation. Patients were re-
cruited for donation under an ethical agreement (06/
Q0108/213) through Institutional Review Board approv-
al. A standardized participant information sheet and con-
sent form were given for completion to those willing to 
participate in the study.
Radiographs from all patients were evaluated prior to 
recruitment and subsequent inclusion into the study in 
order to ensure the absence of further bony pathology. 
Patients displaying radiological evidence of concomitant 
osteoporosis with OA were excluded from the study. 
The degree of cartilage present on the femoral head 
was also assessed under direct vision at the osteoblast 
isolation stage. Patients prescribed immunosuppres-
sant medication such as steroids or disease- modifying 
antirheumatic drugs, who had an underlying diagnosis 
of rheumatoid arthritis (RA), who had been diagnosed 
with renal disease, or who had abnormalities of the 
parathyroid or vitamin D deficiency were also excluded 
from the study.
Seven THA patients and six TKA patients were recruited 
into the study. The mean age of those undergoing THA 
was 79 years (73 to 89; n = 3 males, 4 females) and in 
those undergoing TKA was 71.2 years (68 to 74; n = 3 
males, 3 females).
Cell isolation. Bone samples were obtained from the op-
erating theatre through standardized techniques. Cell 
isolations were performed on samples from the separate 
regions studied using a standard enzyme digestion tech-
nique.22 When femoral heads were dissected, surface car-
tilage was re- examined, and samples were excluded and 
discarded if cartilage was present.
Following thorough washing in phosphate- buffered 
saline (PBS) (Invitrogen, USA), bone fragments were 
digested sequentially in 10 ml of each of the following 
enzymes: trypsin (1 mg/ml; Difco, USA), dispase (2 mg/
ml; Roche, Switzerland), and twice in collagenase A (3 
mg/ml; Roche). The supernatants from the trypsin and 
dispase digestions were discarded whereas those from 
the collagenase digestions were retained and combined.
Collagenase supernatants were centrifuged at 300 g 
for ten minutes and cell pellets resuspended in McCoy’s 
5A medium with stable glutamine without phenol red 
(BioConcep Amimed, Switzerland) containing 10% foetal 
calf serum (FCS) (Invitrogen), 100 units/ml penicillin, 
100 µg/ml streptomycin, 292 µg/ml glutamine (PSG) 
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(Invitrogen), and 30 µg/ml vitamin C (Vitamin C) (Sigma) 
(growth medium).
Flow cytometry of cells from the initial cell isolation. Re- 
suspended cells were counted using a Cell Scepter 
(MilliporeSigma, USA) and 5 × 104 cells per isolate were 
suspended in 100 ml of auto- MACS rinsing solution 
(Miltenyi Biotec, UK) and incubated in 10 µl of the follow-
ing antibodies and control antibodies for 45 minutes on 
ice: anti- alkaline phosphatase (ALP) (Cat. no. FAB1448P, 
IgG1, control cat. no. IC002P, R&D Systems), anti- CD271 
(Cat. no. 130-100-019, control cat. no. 130-104-617, 
Miltenyi Biotec), anti- CD90, CD105, and CD73 (CD90, 
CD105, and CD73 were used as a positive cocktail cat. 
no. 51 to 9007663; positive cocktail control cat. no. 51 
to 9007664, BD Biosciences, USA). The cell populations 
were analyzed on the LSR- Fortessa flow cytometer (BD 
Biosciences; Cambridge Biomedical Research Centre Cell 
Phenotyping Hub).
Cell culture. Cells from the initial isolates were cultured 
in growth medium. The medium was changed every two 
days, cells were used in experiments at passage three, 
and human osteoblast- specific culture conditions and 
medium were used.
Human osteoblasts from the acetabulum, femoral 
neck, and tibial and femoral knee bone were evaluated 
for phenotype and behaviour by measuring proliferation, 
cumulative collagen release, ALP expression, and miner-
alization. Human osteoblasts were cultured in medium 
specific to their growth with and without the addition of 
osteogenic supplements, hydrocortisone (200 nM), and 
β-glycerophosphate (2 mM), to induce cell differentiation 
and provide phosphate for mineralization. Microscopy 
was also used to ensure the distinctive human osteoblast 
morphology was demonstrated and hence cultured.
Cell proliferation. Cells were seeded in six replicate wells 
of a 96- well plate in 180 µl of growth medium at a con-
centration of 2 × 104 cells/ml. At days 1, 3, 7, 11, and 14 
following seeding 20 µl alamarBlue dye (Bio- Rad AbD 
Serotec) was added to each well and incubated for four 
hours.
Following incubation, dye reduction was measured 
as fluorescence intensity (excitation 544 nm, emission 
590 nm) on a FLUOstar Optima microplate reader (BMG 
Labtech). Plates were then washed with PBS and fresh 
growth medium added. Total percentage reduction of 
alamarBlue was calculated for each well at each time-
point and averaged over the six replicates.
Percentage cells expressing ALP by flow cytometry. Cells 
were seeded in 12- well plates at a concentration of 2.5 × 
104 cells/ml using 2 ml in each well with or without beta- 
glycerophosphate (β-GP) (2 mM) and hydrocortisone 
(0.2 µM). At day 1 and 7 post- seeding human osteoblasts 
were assessed for ALP expression.
Cells were pelleted in microcentrifuge tubes (5 × 104/
tube) and resuspended in 100 µl autoMACS rinsing solu-
tion (Milteyni Biotec). A total of 10 µl of R- Phycoerythrin 
(PE) conjugated monoclonal anti- ALP antibody (R&D 
Systems, UK) or 10 µl PE conjugated IgG1 (antibody 
control) was added and incubated for 45 minutes on ice.
After incubation further antibody binding was stopped 
by adding 1 ml of MACS buffer. Cells were then centri-
fuged for five minutes at 300 g, resuspended in 200 µl of 
PBS, and analyzed on a BD Biosciences FACS CantoII flow 
cytometer. This process was then repeated at day 7 for 
untreated and treated human osteoblasts. Results were 
then expressed as percentage expression of the parent 
population.
Data were analyzed using FACS DIVA software and 
Kaluza Flow Cytometry Analysis Software Version 1.2 
(Beckman Coulter, Life Sciences, USA).
Mineralization. Mineral nodule formation was deter-
mined after 14 days. At day 1, cells were seeded at 4 × 
104 cells/ml in 12- well culture plates using 2 ml in each of 
two wells, one containing osteogenic supplements. On 
day 14, cells were washed with PBS, fixed in 70% ethanol 
for 60 minutes on ice, and washed three times thereafter 
using MilliQ water and 2% Alizarin Red S solution, added 
for ten minutes at room temperature to stain the nodules.
After washing the cells in deionized water, images 
of the mineral nodules were captured on a Leitz Dialux 
20 microscope (Leitz Group, Germany). Matrix mineral-
ization was quantified by solubilizing the stain in 10% 
cetylpyridinium and reading the absorbance at 570 nm 
using a Fluostar OPTIMA microplate spectrophotometer 
(BMG Labtech, Germany).
Type 1 collagen dot immunoblotting. Cell supernatants 
corresponding to days 1, 3, 7, 11, and 14 from those seed-
ed to assess mineralization were analyzed by dot- blotting 
using a BioRad Bio- Dot apparatus. Polyvinylidene difluo-
ride (PVDF) membranes were loaded with 50 µl of super-
natant and 50 µl PBS prior to probing with specific type-1 
collagen antibodies (Rockland, USA). Membranes were 
incubated with enhanced chemiluminescence reagents 
(Amersham ECL Western Blotting Detection Reagents, GE 
Healthcare Life Sciences, UK) and quantitation of type-1 
collagen undertaken by densitometry (GS-800 densitom-
eter, BioRad) using a standard curve of purified human 
type-1 collagen. Cumulative collagen release was meas-
ured as mg/ml of culture medium.
Statistical analysis. An initial multivariate analysis of var-
iance (MANOVA) and subsequent post- hoc analysis with 
Tukey’s honestly significant difference (HSD) test was 
used to determine levels of significance. A paired t- test 
was used to compare data between osteoblasts grown 
in growth medium and those grown in mineralization 
medium. A p- value of < 0.05 was considered statistically 
significant.
Previous pilot data within the laboratory exploring 
human osteoblast function demonstrated that sample 
sizes of six or greater were sufficient to produce significant 
differences in osteoblast mineralization between cells 
from the femoral neck and the core of the femoral head. 
Thus, seven patients undergoing THA and six under-
going TKA were considered appropriate to investigate 
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differences using continuous data. Statistical analysis was 
performed using JMP version 12.0.1 (SAS Institute, USA).
Results
Data gathered from the initial cell isolates. In order to bet-
ter categorize heterogeneity within the different anatomi-
cal areas under investigation, cells were isolated and flow 
cytometry was performed to establish if mesenchymal 
stromal cell populations were present and, if so, whether 
they were present at different concentrations and could 
hence lead to differences in cell behaviours at the assay 
stage. Flow cytometry demonstrated low percentage lev-
els of MSC markers; furthermore, no significant differenc-
es were seen in the expression of CD271, CD90, CD105, 
CD73, and ALP between regions when comparing cell 
populations from the femoral neck with the acetabulum 
(MANOVA, CD271 p = 0.175; CD90 p = 0.063; CD105 p 
= 0.900; CD73 p = 0.360; ALP p = 0.243) and the distal 
femur with proximal tibia (CD271 p = 0.315; CD90 p = 
0.060; CD105 p = 0.717; CD73 p = 0.339; ALP p = 0.189, 
all MANOVA) (Figures 1 and 2).
Data of cultured human osteoblasts from patients un-
dergoing primary hip arthroplasty. Figure  3 shows the 
change in metabolic activity of the cultures over the 
14- day experimental period assessed with alamarBlue 
which, during log growth phase, is related to prolifera-
tion. The metabolic activity of femoral neck cells (least 
squares mean 19.7, 95% confidence interval (CI) 17.5 to 
22.0) was significantly greater than that of cells from the 
acetabulum (least squares mean 16.4, 95% CI 14.1 to 
18.6) (p = 0.034, Tukey’s HSD) (Figure 3, Table I).
Cumulative type-1 collagen release also differed 
between human osteoblasts from different regions. 
Femoral neck human osteoblasts produced significantly 
more type-1 collagen (least squares mean 8.6, 95% CI 
7.6 to 9.5) than those from the acetabulum (least squares 
mean 5.2, 95% CI 4.2 to 6.2) (p < 0.001, Tukey’s HSD) 
(Figure 4, Table I).
Fig. 1
Box plot diagram showing percentage expression of CD271, CD90, CD105, 
CD73, and alkaline phosphatase (ALP) of primary isolates of acetabular 
(black box) and femoral neck (grey box) bone. Median, 25% and 75% 
quartiles, and maximum and minimum values are shown. An outlier for ALP 
is also demonstrated on the box plot.
Fig. 2
Box plot diagram showing the percentage expression of CD271, CD90, 
CD105, CD73, and alkaline phosphatase (ALP) of primary isolates of distal 
femoral (black box) and proximal tibial (grey box) bone. Median, 25% and 
75% quartiles, and maximum and minimum values are shown.
Fig. 3
Change in the metabolic activity of human osteoblast cell cultures with time. 
Acetabular human osteoblasts are represented by the smooth line and neck 
cells by the dotted line. Each point shows the mean and standard error of 
the mean.
Table I. Summary of the data from human osteoblasts obtained from those 
patients undergoing primary total hip arthroplasty. The columns show 
which anatomical region the data pertains to with a p- value obtained from 









5.2 8.6 < 0.001




absorbance at 570 nm
1.3 2.2 0.006
*Tukey's honestly significant difference.
ALP, alkaline phosphatase.
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Treatment with β-GP and hydrocortisone increased 
collagen release significantly in acetabular human osteo-
blasts only (least squares mean 6.2, 95% CI 4.4 to 8.0) (p 
= 0.021, paired t- test).
Significantly higher expression of ALP was seen in the 
neck human osteoblasts (least squares mean 62.6, 95% CI 
42.1 to 83.2) when compared to those from the acetab-
ulum (least squares mean 15.8, 95% CI -4.8 to 36.3) as 
shown in Figure 5 and Table I (p = 0.009, Tukey’s HSD).
When treated with β-GP and hydrocortisone, ALP 
expression significantly increased in human osteoblasts 
from the neck (p = 0.002, paired t- test) and the acetab-
ulum (p = 0.029, paired t- test).
Greater mineralization was seen in cultures of cells 
from the femoral neck compared to those from the 
acetabulum (Figure 6). Absorbance of solubilized Alizarin 
Red S stain was significantly greater in human osteoblasts 
from the neck (least squares mean 2.2, 95% CI 1.8 to 2.5) 
than those from the acetabulum (least squares mean 1.3, 
95% CI 0.9 to 1.7) (p = 0.006, Tukey’s HSD) (Table I).
Treatment with β-GP and hydrocortisone increased 
mineralization in acetabular human osteoblasts (p 
= 0.061, paired t- test) but not in cells from the neck 
(Figure 6).
Data of cultured human osteoblasts from patients under-
going primary knee arthroplasty. The metabolic activity 
of the cultures was greater in cells from the tibia (least 
squares mean 32.0, 95% CI 29.2 to 34.6) than the femur 
(least squares mean 29.6, 95% CI 26.9 to 32.3); howev-
er, this difference was not significant (p = 0.228, Tukey’s 
HSD) (Table II).
Type-1 collagen production was significantly greater 
in femoral human osteoblast cultures (least squares mean 
8.1, 95% CI 6.9 to 9.2) than those from the tibia (least 
squares mean 6.2, 95% CI 5.1 to 7.3) (p = 0.021, Tukey’s 
HSD) (Table II). Culturing femoral or tibial human osteo-
blasts in mineralization medium did not significantly alter 
collagen production.
A higher expression of ALP was seen in human osteo-
blasts from the femur (least squares mean 44.4, 95% 
CI 31.7 to 57.0) than those from the tibia (least squares 
Fig. 4
Cumulative collagen release curves over 14 days. Collagen release from 
acetabular human osteoblasts is represented by the smooth line and release 
from neck cells by the dotted line. Each point shows the mean and standard 
error of the mean.
Fig. 5
Box plot diagram of alkaline phosphatase expression on day 1 post- seeding 
of human osteoblasts from the acetabulum and femoral neck. Median and 
25% and 75% quartiles are shown.
Fig. 6
Acetabular and femoral neck human osteoblast cultures at day 14 
after staining with Alizarin Red S. Human osteoblasts were cultured in 
McCoy’s 5A media either with (+) or without (-) hydrocortisone and beta- 
glycerophosphate.
Table II. Summary table of the data from human osteoblasts obtained from 
those patients undergoing primary total knee arthroplasty. The columns 
show which anatomical region the data pertains to with a p- value obtained 








Percentage reduction of alamarBlue 29.6 32.0 0.228
Cumulative collagen release, mg/ml 8.1 6.2 0.021
ALP expression, % of parent 
population
44.4 28.8 0.075
Mineralization, absorbance at 570 
nm
0.82 0.68 0.512
*Tukey's honestly significant difference.
ALP, alkaline phosphatase.
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mean 28.8, 95% CI 16.1 to 41.4) but this was not signif-
icant (p = 0.075, Tukey’s HSD) (Figure  7, Table  II)). 
Treatment with β-GP and hydrocortisone increased 
ALP expression in tibial human osteoblasts (p = 0.004, 
paired t- test) but not femoral human osteoblasts (p = 
0.151, paired t- test).
When comparing mineralization data, human osteo-
blasts from the femur produced greater amounts of 
mineral. Absorbance was higher in femoral human osteo-
blasts (least squares mean 0.82, 95% CI 0.45 to 1.19) than 
those from the tibia (least squares mean 0.68, 95% CI 
0.31 to 1.05), though this was not statistically significant 
(p = 0.512, Tukey’s HSD) (Table II). Treatment with β-GP 
and hydrocortisone did not increase mineral production 
in femoral (p = 0.292, paired t- test) or tibial (p = 0.361, 
paired t- test) human osteoblasts.
Summaries of the data for comparisons of human 
osteoblast activity when harvested from different sites of 
the hip and knee in those undertaking primary THA and 
TKA are illustrated in Tables I and II, respectively, to facili-
tate a comparison of the data.
Discussion
There is a need to study the comparative phenotype 
and behaviour of bone- forming cells from different 
anatomical locations. In this investigation, cells were 
isolated and compared from trabecular bone removed 
from native joints during primary arthroplasty surgery 
from proximal femur and acetabulum, and from distal 
femur and proximal tibia, and investigated as both an 
initial isolate and as a population of cultured cells.
The way human osteoblasts were harvested in this 
study needs some explanation as two methods exist for 
obtaining primary osteoblasts: enzyme digestion,23,24 
and primary outgrowth,25 with the latter often used 
to isolate osteoblasts from non- diseased bone. Both 
methods have been reported to produce a relatively 
homogeneous population, containing predominantly 
early primary human osteoblasts that respond to bone 
morphogenic proteins and glucocorticoid.26,27 Primary 
outgrowth from trabecular fragments avoids enzyme 
cytotoxicity;28 however, this method may select cells 
with higher proliferation and metabolic activity. Many 
studies have advocated enzymatic digestion for osteo-
blast harvest permitting biochemical investigations; 
this has been considered the most satisfactory method 
to study cell- biomaterial interactions,29 and hence 
this method was used in this study. The main effect of 
adding hydrocortisone and β-GP to osteoblasts was to 
increase the number of cells showing ALP expression 
by flow cytometry, which would be expected as the 
effect of hydrocortisone on the differentiation of these 
cells is well recognized. There was no statistically signif-
icant difference between skeletal sites with the addition 
of osteogenic medium. This suggests that cells in all 
cultures were able to respond to hydrocortisone and 
hence were comparable.
We hypothesized that the initial isolate would 
contain bone- lining cells and cells from within the 
bone marrow, and it was important to evaluate the 
initial cell preparations, as these could contain different 
proportions of mesenchymal cells at different stages of 
differentiation, which could account for some of the 
differences in behaviour seen in this study. Flow cytom-
etry showed that there were no significant differences in 
the percentage of cells expressing either markers of early 
mesenchymal cells (CD271, CD73, CD90, and CD105) 
or ALP, as a marker of a more differentiated phenotype, 
when comparing acetabulum with the femoral neck 
or femoral isolates from the knee with those from the 
tibia. The higher differential expression of CD90 (6.6% 
in the acetabular and 0.9% in the femoral neck prepa-
rations) and CD73 (4.9% and 2.8% in acetabular and 
femoral neck preparations, respectively; 20.7% distal 
femur and 18.4% proximal tibia) in the initial isolates 
suggests the presence of adipogenic cells, as expression 
of these markers was higher and they have been asso-
ciated with lipid synthesis and adipocytes.30 Very few 
cells expressing CD105 (0.4% acetabulum and neck; 
femur 0.1%, tibia 0.06%) were present in our prepa-
rations and CD105- negative cells within subpopula-
tions of MSCs have been shown to possess osteogenic 
properties.31
The expression of ALP in initial isolates was not signifi-
cantly different between cells from proximal femur and 
acetabulum or between the two sites in the knee. By 
passage three, human osteoblasts used in the exper-
iments were phenotypically comparable showing a 
spindle shape morphology appropriate for cells of an 
osteoblastic lineage. In addition, at passage 3, a greater 
percentage of cells expressed ALP indicating that many 
were of an osteoblastic lineage and, in the hip, a greater 
percentage of these cells were seen in those cell popula-
tions derived from the femoral neck. This result supports 
the view that there is functional variation in human 
Fig. 7
Box plot diagram of alkaline phosphatase (ALP) expression on day 1 post- 
seeding of human osteoblasts from the femur and tibia. Median and 25% 
and 75% quartiles are shown.
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osteoblasts derived from these different anatomical areas 
that was not evident in the phenotype of the initial cell 
isolate populations. One possible reason for this is that 
there are fewer bone- lining cells in human osteoblast 
isolations from the acetabulum, due to a lower trabecular 
density and reduced trabecular surface area compared to 
the femoral neck. However, counter to this, no difference 
was seen in the percentage of cells expressing CD271 
between isolates from the acetabulum and the proximal 
femur, and trabecular bone- lining cells are known to 
express this marker.32
In the knee, passage three human osteoblasts from 
the tibia showed lower production of type 1 collagen. 
However, proliferation, ALP expression, and the ability to 
mineralize were not significantly different between femur 
and tibia. This suggests that there is a greater similarity 
between human osteoblasts from the distal femur and 
proximal tibia than there is between human osteoblasts 
from the acetabulum and femoral neck.
Data from this project revealed that human osteo-
blasts harvested from the acetabulum demonstrated the 
lowest proliferation rates, produced the lowest amount 
of type-1 collagen, demonstrated the least expression of 
ALP, and produced the least amount of mineral as indi-
cated by the amount of Alizarin Red S stain. During any 
surgical intervention, metalwork, implant fixation, and 
stability are dependent on the surrounding bone and 
the human osteoblasts surrounding these implants are, 
in part, responsible for the biological response of the 
surrounding tissue leading to effective fixation and subse-
quent function following implantation.
There are a number of possible reasons for the differ-
ences seen between human osteoblasts from the acetab-
ulum and the femoral neck. One putative explanation is 
that human osteoblasts from the bone below the trira-
diate cartilage of the acetabulum derive from secondary 
ossification centres and may have a decreased ability to 
form functional osteoblasts compared to those from the 
femoral neck, which are formed from a primary ossifica-
tion centre. Cells from the two sites in the knee are both 
from trabecular bone derived from secondary ossification 
centres below the subchondral bone of the distal femur 
and tibial plateau, which may explain their relative simi-
larity. The response of the skeleton to mechanical load 
is well described and plays a role in both physiological 
and pathophysiological situations, e.g. aseptic loos-
ening. It can be envisaged that the altered mechanical 
environments of the acetabulum and femoral neck may 
contribute to the biological differences found in cell 
populations from these tissues.33 Differences in poten-
tial for differentiation and function engendered by these 
mechanical factors and others provoked by the local envi-
ronments can be maintained by epigenetic memory,34-36 
and could lead to differences in cell function in vitro and, 
by extrapolation, the ability to respond to metalwork or 
an implant in vivo. In OA, it is recognized that subchon-
dral sclerosis is one of the first changes to be seen in the 
acetabulum when compared to the head.37 This links a 
difference in mechanical performance to an altered cell 
response. This increase in bone density in the diseased 
zone is a radiological observation that supports a differ-
ence in human osteoblast activity.
The results in this project have suggested that a differ-
ence exists in the function and behaviour of human osteo-
blasts from acetabular bone and those from the femoral 
neck. The difference between cells from the two periar-
ticular regions in the knee was limited to type-1 collagen 
production only. The biological difference between cells 
isolated from these tissues may reflect the underlying 
biology at these anatomical sites which, in the context 
of surgical intervention in these areas, could inform the 
increased propensity of the acetabular component in the 
hip and the tibial tray in the knee, to loosen.38-41
The main limitation of the study is that the number 
of patient samples is small and we acknowledge that the 
data, while statistically significant, are preliminary. Other 
studies should be carried out aimed at understanding 
differences in cell function between regions of bone rele-
vant to implant fixation.
In summary, the concept of improving the local cell 
environment in order to improve longevity of surgical 
intervention is not new.42,43 Our data demonstrate differ-
ences in osteoblast function at periarticular sites in the 
hip and knee, and the results point to the need for further 
studies investigating the underlying cell biology to estab-
lish if this is an additional aetiology contributing to site- 
dependent differences in surgical outcome.
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